-
Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China
Friday, July 25, 2025 - 2:32pm | 513In a letter to the U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide) and Eli Lilly and Co.’s (NYSE:LLY)...
-
Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case
Friday, July 25, 2025 - 11:28am | 679The Novo Nordisk A/S (NYSE:NVO) attempt to block Mylan Pharmaceuticals from launching a generic version of its weight-loss drug Wegovy hit a major obstacle as the court ruled in Mylan's favor on key infringement claims related to U.S. Patent No. 9,764,003. Read more about the NVO stock price here....
-
Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery
Monday, July 14, 2025 - 2:15pm | 354Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) on Sunday presented new exploratory analyses from its Phase 2 PREVENT and Phase 2b trials of avexitide—an investigational GLP-1 receptor antagonist—at the Endocrine Society's annual meeting (ENDO 2025). The drug targets post-bariatric hypoglycemia (PBH),...
-
Zepbound Powers Eli Lilly's Upbeat Q2 Outlook
Wednesday, July 9, 2025 - 2:55pm | 572Eli Lilly and Co. (NYSE:LLY) is set to release its second-quarter earnings on August 7. According to Benzinga Pro data, analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billion. Expectations are slightly higher for the quarter, primarily driven by the...
-
Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval
Tuesday, July 8, 2025 - 11:58am | 640Novo Nordisk A/S (NYSE:NVO) on Tuesday announced that it has submitted an application to the European Medicines Agency (EMA) for approval of a new, higher dose of its obesity treatment, Wegovy (subcutaneous semaglutide 7.2 mg). The submission is based on clinical data from the STEP UP and STEP UP...
-
WeightWatchers Sheds $1.15 Billion In Debt To Fuel Transformation
Tuesday, July 8, 2025 - 11:48am | 701WW International, Inc. (WeightWatchers) (NASDAQ:WW) announced on Tuesday the successful completion of its strategic reorganization process. WeightWatchers implemented a financial reorganization transaction in May to strengthen its financial position and increase investment flexibility. The...
-
Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report
Tuesday, July 1, 2025 - 11:05am | 582Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its obesity drug Wegovy. As rival Eli Lilly and Co.’s (NYSE:LLY) Zepbound gains momentum, the Danish pharmaceutical giant is grappling with the fallout of those early...
-
Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs
Friday, June 27, 2025 - 9:39am | 964Against a backdrop of regulatory scrutiny, with Spain investigating Novo Nordisk for alleged covert advertising of its popular weight-loss drugs, the U.K. is initiating research to determine if genetic factors impact the risk of acute pancreatitis associated with GLP-1 injections. Yellow Card...
-
US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows
Wednesday, June 25, 2025 - 2:50pm | 560Although glucagon-like peptide-1 (GLP-1) agonists have shown promising results in reducing weight and cardiovascular risks, new data reveals that many U.S. adults struggle to stay on long-term treatment. While newer obesity-indicated GLP-1 therapies, such as semaglutide and tirzepatide, are...
-
What's Going On With Viking Therapeutics Stock On Wednesday?
Wednesday, June 25, 2025 - 1:01pm | 793Viking Therapeutics, Inc. (NASDAQ:VKTX) on Wednesday initiated the VANQUISH Phase 3 clinical program for VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in oral and...
-
Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues
Tuesday, June 24, 2025 - 2:54pm | 736Amgen Inc (NASDAQ:AMGN) announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In the Phase 2 study, MariTide demonstrated up to...
-
Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly
Tuesday, June 24, 2025 - 10:38am | 612Novo Nordisk A/S (NYSE:NVO) has reportedly launched its weight-loss drug Wegovy (semaglutide) in India to compete with Eli Lilly And Co. (NYSE:LLY). In March this year, U.S. pharma giant Eli Lilly launched its popular weight loss drug Mounjaro (tirzepatide) in India. It is expected to have the...
-
Hims CEO Slams Novo Nordisk For 'Anticompetitive Demands' After Ozempic Maker Abruptly Ends Partnership: 'We Refuse To Be Strong-Armed'
Tuesday, June 24, 2025 - 3:06am | 899Hims & Hers Health Inc. (NYSE:HIMS), CEO Andrew Dudum, has accused Novo Nordisk of exerting anticompetitive pressure to prioritize its weight-loss drug Wegovy over patient needs after the abrupt termination of its partnership with a pharmaceutical giant. Check out the current price of HIMS...
-
Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update
Monday, June 23, 2025 - 4:24pm | 499Amgen Inc (NASDAQ:AMGN) shares are trading lower by 5.7% to $272.88 Monday afternoon after the company released full results from part one of its phase two study of MariTide, its investigational obesity treatment. What To Know: The therapy, a long-acting, peptide-antibody conjugate administered...
-
Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern
Monday, June 23, 2025 - 9:10am | 944On Sunday, The New England Journal of Medicine (NEJM) published results from Novo Nordisk A/S‘ (NYSE:NVO) phase 3 REDEFINE 1 trial of CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes...